• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Neuropace, Inc. - Common Stock (NQ:NPCE)

    14.74 -1.06 (-6.68%)
    Streaming Delayed Price Updated: 1:12 PM EDT, May 13, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 176,292
    Open 14.83
    Bid (Size) 14.70 (100)
    Ask (Size) 14.78 (200)
    Prev. Close 15.80
    Today's Range 13.65 - 15.20
    52wk Range 7.562 - 19.60
    Shares Outstanding 24,296,259
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    NeuroPace Q1 Earnings Call Highlights ↗
    NeuroPace (NASDAQ:NPCE) raised its 2026 revenue outlook after reporting first-quarter results that management said reflected continued demand for its RNS System and improving commercial execution... 
    Via MarketBeat
    Topics Artificial Intelligence Earnings
    NeuroPace (NASDAQ:NPCE) Beats Q1 Estimates, Raises Full-Year Revenue Guidance ↗
    Via Chartmill

    Performance

    YTD
    -2.8%
    -2.8%
    1 Month
    -0.9%
    -0.9%
    3 Month
    -3.5%
    -3.5%
    6 Month
    +9.3%
    +9.3%
    1 Year
    +10.3%
    +10.3%

    More News

    Read More
    News headline image
    NeuroPace Reports First Quarter 2026 Financial Results and Raises 2026 Revenue Guidance
    From NeuroPace, Inc.
    Via Business Wire
    News headline image
    NeuroPace to Report First Quarter 2026 Financial Results on May 12, 2026
    From NeuroPace, Inc.
    Via Business Wire
    News headline image
    NeuroPace Highlights Expanding Clinical Evidence Leadership with Published 3-Year Post-Approval Study (PAS) Results in Neurology and NAUTILUS Presentation at AAN 2026
    From NeuroPace, Inc.
    Via Business Wire
    NeuroPace Inc (NASDAQ:NPCE) Beats Q4 2025 Estimates and Reiterates 2026 Outlook ↗
    Via Chartmill
    News headline image
    NeuroPace to Present at the 25th Annual Needham Virtual Healthcare Conference
    From NeuroPace, Inc.
    Via Business Wire
    News headline image
    NeuroPace to Present at the Leerink Global Healthcare Conference
    From NeuroPace, Inc.
    Via Business Wire
    News headline image
    Why NeuroPace Stock Was Inching Higher on Wednesday ↗
    Via The Motley Fool
    News headline image
    NeuroPace (NPCE) Q4 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    NeuroPace Reports Fourth Quarter and Full Year 2025 Financial Results and Reiterates 2026 Outlook
    From NeuroPace, Inc.
    Via Business Wire
    News headline image
    NeuroPace to Report Fourth Quarter 2025 Financial Results on March 3, 2026
    From NeuroPace, Inc.
    Via Business Wire
    News headline image
    NeuroPace Reports Preliminary Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook
    From NeuroPace, Inc.
    Via Business Wire
    News headline image
    NeuroPace to Present at the 44th Annual J.P. Morgan Healthcare Conference
    From NeuroPace, Inc.
    Via Business Wire
    News headline image
    NeuroPace Files PMA Supplement to FDA Seeking Expanded RNS® System Indication for Idiopathic Generalized Epilepsy
    From NeuroPace, Inc.
    Via Business Wire
    News headline image
    NeuroPace Announces Positive 18-Month NAUTILUS Trial Results in Idiopathic Generalized Epilepsy
    From NeuroPace, Inc.
    Via Business Wire
    News headline image
    NeuroPace to Highlight Life-Changing Outcomes and AI-Powered Confident Care at the 2025 American Epilepsy Society (AES) Annual Meeting
    From NeuroPace, Inc.
    Via Business Wire
    News headline image
    NeuroPace Announces Favorable Medicare Reimbursement Increases for RNS System Physician and Hospital Outpatient Services
    From NeuroPace, Inc.
    Via Business Wire
    News headline image
    NeuroPace (NPCE) Q3 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings World Trade
    News headline image
    These stocks are moving in today's session ↗
    Via Chartmill
    News headline image
    Keep an eye on the top gainers and losers in Wednesday's session. ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
    Via Benzinga
    News headline image
    Johnson Controls, Babcock & Wilcox, Lemonade, Lumentum, Teva Pharmaceutical And Other Big Stocks Moving Higher On Wednesday ↗
    Via Benzinga
    News headline image
    Wednesday's session: gap up and gap down stocks ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
    Via Benzinga

    Frequently Asked Questions

    Is Neuropace, Inc. - Common Stock publicly traded?
    Yes, Neuropace, Inc. - Common Stock is publicly traded.
    What exchange does Neuropace, Inc. - Common Stock trade on?
    Neuropace, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Neuropace, Inc. - Common Stock?
    The ticker symbol for Neuropace, Inc. - Common Stock is NPCE on the Nasdaq Stock Market
    What is the current price of Neuropace, Inc. - Common Stock?
    The current price of Neuropace, Inc. - Common Stock is 14.74
    When was Neuropace, Inc. - Common Stock last traded?
    The last trade of Neuropace, Inc. - Common Stock was at 05/13/26 01:12 PM ET
    What is the market capitalization of Neuropace, Inc. - Common Stock?
    The market capitalization of Neuropace, Inc. - Common Stock is 358.25M
    How many shares of Neuropace, Inc. - Common Stock are outstanding?
    Neuropace, Inc. - Common Stock has 358M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.